0001209191-22-005503.txt : 20220128 0001209191-22-005503.hdr.sgml : 20220128 20220128195306 ACCESSION NUMBER: 0001209191-22-005503 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220126 FILED AS OF DATE: 20220128 DATE AS OF CHANGE: 20220128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aggarwal Gaurav CENTRAL INDEX KEY: 0001551965 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37490 FILM NUMBER: 22570831 MAIL ADDRESS: STREET 1: C/O PANORAMA CAPITAL STREET 2: 2440 SAND HILL ROAD, SUITE 302 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sierra Oncology, Inc. CENTRAL INDEX KEY: 0001290149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1820 GATEWAY DRIVE STREET 2: SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: (605) 376-8679 MAIL ADDRESS: STREET 1: 1820 GATEWAY DRIVE STREET 2: SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: ProNAi Therapeutics Inc DATE OF NAME CHANGE: 20040513 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-26 0 0001290149 Sierra Oncology, Inc. SRRA 0001551965 Aggarwal Gaurav C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404 1 0 1 0 Common Stock 2022-01-26 4 X 0 480277 13.20 A 1935853 I By Vivo Opportunity Fund, L.P. Series B Warrant (Right to Purchase) 13.20 2022-01-26 4 X 0 1455384 13.20 D 2020-01-22 Common Stock 480277 0 I By Vivo Opportunity Fund, L.P. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund, L.P. The Reporting Person may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. with four other managing members of Vivo Opportunity, LLC. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis. /s/ Sukhi Jagpal as attorney-in-fact for Gaurav Aggarwal 2022-01-28